2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Robert L. Coleman, MD, FACOG, FACS, discusses the potential to move immunotherapy into earlier lines of treatment in cervical cancer.
Robert L. Coleman, MD, FACOG, FACS, chief scientific officer of The US Oncology Network, discusses the potential to move immunotherapy into earlier lines of treatment in cervical cancer.
The introduction of immunotherapy to the cervical cancer paradigm has been welcome as limited treatment options are available to these patients. Looking to ongoing research, the field hopes to sequence immunotherapy earlier into treatment, Coleman explains.
For example, the concept of utilizing immunotherapy plus radiation therapy followed by maintenance therapy could be beneficial in the adjuvant and localized disease settings, Coleman explains. Throughout 2021, it is likely that data regarding this approach will read out. Moreover, as the treatment landscape of cervical cancer has been relatively stagnant in recent years, the potential to offer a new treatment approach to patients with cervical cancer is exciting, Coleman concludes.